EnCompass Technologies, Inc.
The objective of this pivotal study is to compare the safety and effectiveness of the F2 CPC (Treatment group) to a Control group (no embolic protection) in participants undergoing transfemoral (TF) TAVR with commercially available devices.
The study is designed to demonstrate that the F2 CPC performs in a consistent manner as the control group in terms of safety, and the F2 Cerebral Protection Catheter (CPC) will be superior in performance when compared to the control group in terms of effectiveness in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR).
Key Inclusion Criteria: 1. Age ≥ 21 and ≤ 90 years 2. Patient meets the established criteria and indications for commercially available TAVR (e.g., balloon expandable SAPIEN valve platform, self-expanding CoreValve platform, or Navitor TAVI System) via transfemoral access and is scheduled to undergo TAVR per their treating physician. 3. Patient is willing and able to comply with protocol-specified follow-up evaluations. 4. Patient is able and willing to provide written informed consent Key Exclusion Criteria: General Exclusion Criteria: Participants are not eligible for the study if any of…
Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure
Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device